MX2017015985A - Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida con los mismos. - Google Patents

Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida con los mismos.

Info

Publication number
MX2017015985A
MX2017015985A MX2017015985A MX2017015985A MX2017015985A MX 2017015985 A MX2017015985 A MX 2017015985A MX 2017015985 A MX2017015985 A MX 2017015985A MX 2017015985 A MX2017015985 A MX 2017015985A MX 2017015985 A MX2017015985 A MX 2017015985A
Authority
MX
Mexico
Prior art keywords
adsorption
polysaccharide
methods
improving
vaccine formulation
Prior art date
Application number
MX2017015985A
Other languages
English (en)
Inventor
Shankar Pisal Sambhaji
Mhalasakant Dhere Rajeev
Kumar Malviya Hitesh
Dinesh Mallya Asha
MAHOR Sunil
Maheshkumar Gautam Manish
Vilas JOSHI Chetan
Vamsi Krishna Malepati Venkata
Kumar Jana Swapan
Shivaji Jadhav Prashant
Original Assignee
Serum Inst Of India Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Private Ltd filed Critical Serum Inst Of India Private Ltd
Publication of MX2017015985A publication Critical patent/MX2017015985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para la preparación de formulaciones estables de vacunas antineumocóccicas conjugadas de polisacárido-proteína multivalentes. Las formulaciones estables de la presente presentan un porcentaje óptimo de adsorción para cada conjugado, en donde se puede prevenir la agregación mediante el uso de i) una adsorción individual o separada de conjugados que de lo contrario presentan un porcentaje de adsorción menor con una adsorción combinada ii) un sistema de solución amortiguadora de histidina-ácido succínico junto con un cambio en el pH de pH neutro a pH ácido iii) una relación de polisacárido a proteína de 0,5 a aproximadamente 1,4 iv) un impulsor de turbina tipo Rushton de seis hojas en los recipientes de formulación.
MX2017015985A 2015-06-08 2016-06-03 Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida con los mismos. MX2017015985A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2185MU2015 2015-06-08
PCT/IB2016/053265 WO2016199003A1 (en) 2015-06-08 2016-06-03 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Publications (1)

Publication Number Publication Date
MX2017015985A true MX2017015985A (es) 2018-08-15

Family

ID=57503115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015985A MX2017015985A (es) 2015-06-08 2016-06-03 Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida con los mismos.

Country Status (17)

Country Link
US (1) US10729780B2 (es)
EP (1) EP3302542A4 (es)
JP (2) JP7258463B2 (es)
KR (2) KR102690378B1 (es)
CN (1) CN107847571A (es)
AU (2) AU2016276269B2 (es)
CA (1) CA2988366C (es)
CO (1) CO2017012628A2 (es)
EA (1) EA201792470A1 (es)
IL (1) IL256118B (es)
MX (1) MX2017015985A (es)
MY (1) MY187461A (es)
PE (1) PE20180460A1 (es)
PH (1) PH12017502244A1 (es)
SA (1) SA517390495B1 (es)
WO (1) WO2016199003A1 (es)
ZA (1) ZA201708325B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220774A1 (es) 2015-05-04 2022-05-16 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
PE20180460A1 (es) * 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos
CN106822884B (zh) * 2016-12-28 2021-04-30 北京民海生物科技有限公司 一种多价肺炎球菌荚膜多糖结合疫苗的制备方法
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
PT3585803T (pt) * 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3678655A4 (en) * 2017-09-07 2021-05-05 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
CN108524926B (zh) * 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
GB201818517D0 (en) * 2018-11-13 2018-12-26 Univ Liverpool John Moores Nanoparticles and uses thereof
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2021014710A (es) * 2019-06-05 2022-01-18 Merck Sharp & Dohme Llc Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo.
US12473379B2 (en) 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
CN113607939B (zh) * 2021-08-05 2024-10-22 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法
CN115006522B (zh) * 2022-06-16 2025-08-22 北京智飞绿竹生物制药有限公司 一种双价痢疾结合物组合疫苗的制备方法
CA3232076A1 (en) * 2023-04-17 2025-04-14 Serum Institute Of India Private Limited Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
CN100423774C (zh) 2003-08-06 2008-10-08 美国政府健康及人类服务部 制备多糖-蛋白轭合物疫苗的方法
JP2008536515A (ja) * 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
PL1973564T3 (pl) * 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
JP2009520771A (ja) * 2005-12-23 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム コンジュゲートワクチン
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
SI2167121T1 (sl) * 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
AR084158A1 (es) * 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
DK2809349T3 (da) 2012-01-30 2019-02-18 Serum Institute Of India Pvt Ltd Immunogen sammensætning
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
SI2885007T1 (sl) * 2012-08-16 2018-12-31 Pfizer Inc. Postopki in kompozicije glikokonjugacij
CN103893751B (zh) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
PE20180460A1 (es) * 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos

Also Published As

Publication number Publication date
EP3302542A1 (en) 2018-04-11
EA201792470A1 (ru) 2018-10-31
SA517390495B1 (ar) 2023-03-23
AU2024202450A1 (en) 2024-10-31
KR20180030498A (ko) 2018-03-23
AU2016276269B2 (en) 2021-01-28
IL256118A (en) 2018-02-28
MY187461A (en) 2021-09-23
JP2021185152A (ja) 2021-12-09
EP3302542A4 (en) 2019-04-10
KR102876828B1 (ko) 2025-10-27
KR20240007690A (ko) 2024-01-16
PE20180460A1 (es) 2018-03-06
CA2988366A1 (en) 2016-12-15
IL256118B (en) 2021-12-01
CN107847571A (zh) 2018-03-27
ZA201708325B (en) 2019-05-29
NZ738090A (en) 2023-09-29
JP2018516962A (ja) 2018-06-28
WO2016199003A1 (en) 2016-12-15
CA2988366C (en) 2021-12-07
JP7258463B2 (ja) 2023-04-17
US10729780B2 (en) 2020-08-04
KR102690378B1 (ko) 2024-08-01
PH12017502244A1 (en) 2018-06-11
CO2017012628A2 (es) 2018-03-28
US20180161445A1 (en) 2018-06-14
AU2016276269A1 (en) 2018-01-18
BR112017026343A2 (pt) 2019-11-19

Similar Documents

Publication Publication Date Title
CO2017012628A2 (es) Métodos para mejorar la adsorción de conjugados de polisacárido-proteína y una formulación de vacuna multivalente obtenida con los mismos
BR112020004502A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
CO2019002955A2 (es) Composiciones de vacuna neumocócica multivalente que comprenden conjugados de polisacáridos y proteínas
BR112020004509A8 (pt) Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
AR092897A1 (es) Composiciones inmunogenicas
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
CO7240387A2 (es) Composición conjugada de polisacáridos-proteínas neumocócica polivalente
EA201890400A1 (ru) Способы и композиции для иммунной защиты против внекишечной патогенной e. coli
BR112015013560A8 (pt) Composição imunogênica multivalente; e composição farmacêutica para induzir uma resposta imunológica aos conjugados de polissacarídeo capsular de streptococcus pneumoniae
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
BRPI0800867A2 (pt) concentrado embalado, processo para a preparaÇço de um concentrado embalado e uso de um concentrado
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
BR112013002940A2 (pt) adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
BR112018075785A2 (pt) formulação de vacina para o hiv
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
BRPI0801060A2 (pt) concentrado embalado, processo para preparaÇço de um concentrado embalado e uso de um concentrado
NZ630990A (en) Aminoacid lipids
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
BR112015025392A2 (pt) composição de vacina e método de utilização
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.